U.S. Entertainment Stock News

NasdaqGS:UMBF
NasdaqGS:UMBFBanks

Legence And 2 Other Stocks That May Be Priced Below Estimated Value

As the U.S. market grapples with rising Treasury yields and uncertainty surrounding Federal Reserve decisions, investors are keenly observing potential opportunities amid recent index declines. In this environment, identifying undervalued stocks can be crucial for those looking to capitalize on discrepancies between market price and estimated value, as these stocks might offer growth potential despite broader economic challenges.
NasdaqGM:ACRV
NasdaqGM:ACRVBiotechs

Penny Stocks To Watch In January 2026

As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past market trends, continue to offer intriguing possibilities for those willing to explore smaller or newer companies at accessible price points. By focusing on solid financials and growth potential, these stocks can present unique opportunities for investors looking to tap into under-the-radar...
NasdaqGS:THFF
NasdaqGS:THFFBanks

US Market's Undiscovered Gems Three Promising Small Caps

As the U.S. market grapples with rising Treasury yields and a cautious Federal Reserve outlook, small-cap stocks are navigating a landscape marked by both challenges and opportunities. In this environment, identifying promising small caps requires a keen eye for companies with robust fundamentals that can weather economic fluctuations and capitalize on niche market demands.
NYSEAM:SDEV
NYSEAM:SDEVPharmaceuticals

Assessing NovaBay Pharmaceuticals (NBY) Valuation After Digital Asset Financing And SKY Token Treasury Shift

NovaBay Pharmaceuticals (NBY) has reshaped its story with a private placement of pre funded warrants totaling about US$134 million, largely paid in digital assets, and a pivot toward a SKY token focused treasury model. See our latest analysis for NovaBay Pharmaceuticals. The financing news comes after a very sharp 30 day share price return of 178.68% and a very large 1 year total shareholder return, although the 3 and 5 year total shareholder returns are still deeply negative, so long term...
NasdaqGS:NAVI
NasdaqGS:NAVIConsumer Finance

Navient’s CFO and Oversight Shake-Up Might Change The Case For Investing In Navient (NAVI)

In early January 2026, Navient Corporation reshaped its leadership structure, appointing long-time executive Steve Hauber as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, while Joe Fisher exited the CFO role and began a short transition period before leaving the company. By consolidating finance, legal, risk management, internal audit, and compliance under Hauber and expanding COO Troy Standish’s remit to technology and human resources, Navient is...
NYSE:PAR
NYSE:PARSoftware

Should Winning Papa Johns as Core AI Platform Partner Require Action From PAR Technology (PAR) Investors?

Papa Johns previously announced it selected PAR Technology’s PAR POS and PAR OPS platforms to underpin its next-generation U.S. in-restaurant technology stack, replacing legacy on-premise systems and targeting a fully rolled-out deployment across all domestic corporate and franchise locations by the end of 2027. This deal reinforces PAR’s role as an integrated restaurant tech provider, embedding its AI-enabled platform at scale within a major quick-service pizza chain’s operations and...
NYSE:THS
NYSE:THSFood

Will FMR’s Sharp Stake Cut Test Investor Confidence in TreeHouse Foods’ (THS) Efficiency Execution Narrative?

On December 31, 2025, FMR LLC sharply cut its holdings in TreeHouse Foods Inc, reducing its position by 2,718,583 shares while retaining 822,158 shares and a 1.60% stake. This sizeable pullback by a major institutional investor brings fresh attention to TreeHouse Foods’ ability to execute its efficiency plans amid ongoing market and operational challenges. We’ll now examine how FMR LLC’s large reduction in its TreeHouse stake interacts with the existing investment narrative and risk...
NasdaqGM:SPRY
NasdaqGM:SPRYBiotechs

Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray

China approval puts focus on ARS Pharmaceuticals’ new market opportunity ARS Pharmaceuticals (SPRY) is back on investor radar after partner Pediatrix Therapeutics received approval from China’s National Medical Products Association for community use of neffy, its intranasal epinephrine spray. This decision makes neffy the first government approved epinephrine product for use outside Chinese hospitals. It creates a fresh addressable market and sets up ARS to collect regulatory milestone...